EU Marketing Authorization Holder: Roles, Responsibilities & Regulatory Compliance

EU Marketing Authorization Holders oversee the entire lifecycle of medicinal products, ensuring they meet strict safety, effectiveness, and quality standards. They follow European Medicines Agency guidelines, maintain regulatory compliance, and submit timely reports to authorities. They also implement monitoring systems to continuously track product safety and protect patient health.

What Is a Marketing Authorization Holder (MAH)?

The European Medicines Agency (EMA) plays an important role in supporting the development of medicines and improving access to them across the European Union (EU). It evaluates applications for marketing authorization, monitors the safety of medicines throughout their lifecycle, and provides information to healthcare professionals and patients.

Before a pharmaceutical product can be sold or supplied in the market, it must obtain a valid Marketing Authorization for both human and veterinary medicines. The organization that holds this authorization is known as the MAH. The EU Marketing Authorization Holder is responsible for marketing the product according to the conditions and guidelines specified in the authorization.

Marketing authorization is granted only after evaluating safety, quality, and efficacy data, and approval is given only when the benefits outweigh the potential risks.¹

Roles and Responsibilities of the MAH

The EU Marketing Authorization Holder plays an important role in ensuring that a medicinal product placed in the market remains safe, effective, and compliant with regulatory requirements. The MAH is legally responsible for the medicinal product throughout its lifecycle, from approval to post-marketing stages.² Even if the MAH appoints a representative for marketing or regulatory activities, the overall legal responsibility remains with the MAH. Therefore, the MAH must ensure that all regulatory guidelines and national rules are followed when the product is marketed and sold in different regions.

Table 1: Marketing Authorization Holder responsibilities 

The MAH ensures that the medicinal product placed on the market continues to meet regulatory standards, maintain quality, and protect patient safety throughout its lifecycle.³

Guidelines MAHs Should Follow

MAHs in the EU are required to follow scientific and regulatory guidelines issued by the EMA to ensure that medicines meet the required standards of quality, safety, and efficacy. These guidelines are prepared by the Committee for Medicinal Products for Human Use (CHMP) in consultation with regulatory authorities of EU Member States. They provide a harmonised framework for interpreting regulatory requirements and support applicants in preparing marketing authorisation applications in a structured manner.

Key Guidelines Followed by MAHs

• Quality Guidelines: Focus on manufacturing, quality control, and lifecycle management of medicines.
• Clinical Efficacy and Safety Guidelines: Evaluate the safety and effectiveness of medicinal products.
• Non-clinical Guidelines: Include toxicology studies and environmental risk assessments.
• International Council for Harmonisation (ICH) Guidelines: Provide internationally harmonised standards for drug development.
• Multidisciplinary Guidelines: Cover areas such as biosimilars, paediatrics, and pharmacogenomics.

The EMA encourages MAHs to follow these guidelines carefully. If any deviation occurs, it must be clearly justified during the submission process. MAHs are also advised to seek scientific advice from the agency before making any deviations during medicine development.⁴

Regulatory Compliance of MAHs

EU drug marketing authorization holders must ensure that their applications comply with regulatory and quality requirements established by the EMA. During the submission of a marketing authorisation application, applicants are required to provide accurate and complete information related to manufacturing, non-clinical studies, and clinical studies. This documentation helps regulatory authorities confirm that the medicinal product meets the necessary standards of quality, safety, and efficacy.

• GMP Compliance: Applicants must confirm that manufacturing sites follow Good Manufacturing Practice and provide correct details of site names, addresses, and manufacturing activities in the application dossier.
• GLP Compliance: Non-clinical studies must follow Good Laboratory Practice and provide information about study title, test facilities, and inspection status.
• GCP Compliance: Clinical studies should comply with Good Clinical Practice and include investigator site details and study reports.⁵

These medicinal product compliance EU requirements support effective evaluation and approval of medicinal products.

Reporting Requirements for MAHs

EU Marketing Authorization Holders are legally required to submit and maintain accurate information about their authorised medicinal products with the EMA. This obligation is established under Article 57(2) of Regulation (EC) No. 726/2004 and applies to all MAHs operating in the EU and the European Economic Area (EEA).

• Submission of New Authorisations: MAHs must submit details of newly granted marketing authorisations within 15 calendar days of notification by the competent authority.
• Scope of Reporting: This requirement applies to centrally authorised products, nationally authorised products, and those approved through mutual recognition or decentralised procedures.
• Updates and Amendments: Any changes such as variations, transfers, renewals, suspensions, revocations, or withdrawals must be reported to the EMA within 30 calendar days.

These reporting obligations help ensure transparency and proper regulatory monitoring of medicinal products in the EU.⁶

Pharmacovigilance System Requirements for MAHs

Applicants for marketing authorisation must provide a detailed summary of their pharmacovigilance system in the application dossier. This ensures that the EU pharmacovigilance MAH has robust processes to monitor the safety of medicinal products throughout their lifecycle. Key requirements include:

• Qualified Person for Pharmacovigilance (QPPV): The MAH must appoint a qualified person responsible for pharmacovigilance who resides and operates within the EU.
• Pharmacovigilance System Master File (PSMF): A detailed description of the pharmacovigilance system must be maintained and made available for regulatory inspection when requested.
• Submission of System Summary: The applicant must include a signed statement confirming that adequate systems and resources are available to perform pharmacovigilance activities.

These requirements ensure that the safety of medicinal products is continuously monitored after authorisation.⁵

Conclusion

EU MAH services ensure medicinal products are safe, effective, and compliant throughout their lifecycle. By following EMA regulatory requirements and guidelines, submitting timely reports, and implementing a robust pharmacovigilance system, MAHs safeguard patient safety and uphold the quality, efficacy, and transparency of medicines across the EU.

Summary 

• EU Marketing Authorization Holders are legally responsible for the safety, quality, and regulatory compliance of medicines throughout their lifecycle.
• They follow scientific guidelines covering manufacturing, clinical studies, non-clinical studies, and international standards.
• Compliance is maintained through proper manufacturing practices, laboratory practices, and clinical study standards, with timely reporting of any changes.
• Continuous monitoring systems ensure the safety of medicinal products after authorization, protecting patients throughout the product’s use.

References 

1. Navale SA, Basarkar GD. Overview of Drug Approval Process and Post Approval Changes in Europe. Int J Drug Reg Affairs. 2023;11(4):1-15. doi:10.22270/ijdra.v11i4.627

2. Medical writing in pharmacovigilance: An overview – IP Int J Compr Adv Pharmacol. Accessed March 10, 2026. https://ijcap.in/archive/volume/9/issue/4/article/3438?utm_source=chatgpt.com#R251350632073714

3. Muhaned Al-Hindawi. Marketing authorization and licensing of medicinal products in EU. In: Drug Delivery Trends. Elsevier; 2020:45-75. doi:10.1016/B978-0-12-817870-6.00003-1

4. Scientific guidelines | European Medicines Agency (EMA). Accessed March 10, 2026. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines

5. Pre-authorisation guidance | European Medicines Agency (EMA). Accessed March 10, 2026. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance?utm_source=chatgpt.com#section-34-compliance-environmental-risk-assessment-and-pharmacovigilance-68986. Reporting requirements for marketing-authorisation holders | European Medicines Agency (EMA). Accessed March 10, 2026.